The conference provides in-depth discussions and analyses on a wide variety of timely topics by bringing together experts from the federal government, industry, the private bar, non-profit, patient and consumer advocates, consulting organizations, and academia.

FDA and the Federal Government have recently enacted a variety of initiatives, including draft guidance and legislation, to promote clinical trial diversity enrollment, encourage decentralized clinical trials, and streamline clinical trials. In this session, panelists will explore why clinical trial diversity matters and the barriers and opportunities to advancing it, including remote participation and using technology to recruit diverse populations. Panelists also will discuss the recent draft guidance, federal legislation, and complementary initiatives, such as increasing diversity among clinical trial administrators and healthcare providers.